Relay Closes $35 Million Series B Funding to Drive Greater Productivity and Safety for Frontline Businesses and Workers

Led by G2 Venture Partners, funding will fuel Relay's rapid growth and innovation of new products to serve industries ranging from hospitality to healthcareRALEIGH, N.C., June 10, 2024 /PRNewswire/ -

PR NewswireJun 10 08:00 ET

Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 29% Of Holding

Anyone interested in Relay Therapeutics, Inc. (NASDAQ:RLAY) should probably be aware that the Chief Corporate Development Officer, Peter Rahmer, recently divested US$129k worth of shares in the compan

Simply Wall StJun 8 08:54 ET

Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28

Stifel analyst Bradley Canino maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 41.8% and a

moomoo NewsJun 7 14:32 ET · Ratings

A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $15 to $28

On Jun 07, major Wall Street analysts update their ratings for $Relay Therapeutics(RLAY.US)$, with price targets ranging from $15 to $28.BofA Securities analyst Jason Gerberry maintains with a buy rat

moomoo NewsJun 7 09:00 ET · Ratings

Relay Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 172.85% HC Wainwright & Co. $20 → $20 Reiterates Buy → Buy 05/10/2024 104.64% Barclays $15 → $1

BenzingaJun 7 06:56 ET

Express News | Relay Therapeutics Inc : Leerink Partners Raises Target Price to $19 From $18

ReutersJun 6 23:44 ET